{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:21:44Z","timestamp":1771687304779,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40261-023-01301-7","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T12:02:27Z","timestamp":1693828947000},"page":"669-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Calcitonin Gene-Related Peptide Monoclonal\u00a0Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies"],"prefix":"10.1007","volume":"43","author":[{"given":"Vinicius L.","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Felipe F.","family":"Mainka","sequence":"additional","affiliation":[]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"1301_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-020-00997-1","volume":"41","author":"DK Ha","year":"2021","unstructured":"Ha DK, Kim MJ, Han N, Kwak JH, Baek IH. Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: updated meta-analysis. Clin Drug Investig. 2021;41:119\u201332.","journal-title":"Clin Drug Investig"},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59:306\u201338.","journal-title":"Headache"},{"key":"1301_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397:1485\u201395.","journal-title":"Lancet"},{"key":"1301_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1526-4610.2011.01954.x","volume":"51","author":"RB Lipton","year":"2011","unstructured":"Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache J Head Face Pain. 2011;51:77\u201383.","journal-title":"Headache J Head Face Pain."},{"key":"1301_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139.","journal-title":"Neurology"},{"key":"1301_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2040622315579627","volume":"6","author":"MW Weatherall","year":"2015","unstructured":"Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6:115\u201323.","journal-title":"Ther Adv Chronic Dis."},{"key":"1301_CR7","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician. 2019;99:17\u201324.","journal-title":"Am Fam Physician"},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/head.12550","volume":"55","author":"WJ Becker","year":"2015","unstructured":"Becker WJ. Acute migraine treatment in adults. Headache. 2015;55:778\u201393.","journal-title":"Headache"},{"key":"1301_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2021.1640","volume":"325","author":"MS Robbins","year":"2021","unstructured":"Robbins MS. Diagnosis and management of headache: a review. JAMA. 2021;325:1874\u201385.","journal-title":"JAMA"},{"issue":"23","key":"1301_CR10","first-page":"67","volume":"2022","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. Expert Opin Pharmacother. 2022;2022(23):67.","journal-title":"Expert Opin Pharmacother"},{"key":"1301_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.11607\/ofph.3163","volume":"37","author":"N George","year":"2023","unstructured":"George N, Tepper SJ. Novel migraine treatments: a review. J Oral Facial Pain Headache. 2023;37:25\u201332.","journal-title":"J Oral Facial Pain Headache"},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"333102423115936","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler E-M, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43:3331024231159366.","journal-title":"Cephalalgia"},{"key":"1301_CR13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/head.13907","volume":"60","author":"RB Forbes","year":"2020","unstructured":"Forbes RB, McCarron M. Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis. Headache. 2020;60:1542\u201357.","journal-title":"Headache"},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","volume":"209","author":"P Soni","year":"2021","unstructured":"Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021;209:106893.","journal-title":"Clin Neurol Neurosurg"},{"key":"1301_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24:56.","journal-title":"J Headache Pain"},{"key":"1301_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ene.15563","volume":"30","author":"F Vernieri","year":"2023","unstructured":"Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, et al. Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study. Eur J Neurol. 2023;30:224\u201334.","journal-title":"Eur J Neurol"},{"issue":"23","key":"1301_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"2022","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, Onofrio F, Finocchi C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;2022(23):138.","journal-title":"J Headache Pain"},{"key":"1301_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40261-018-0624-6","volume":"38","author":"VL Ferreira","year":"2018","unstructured":"Ferreira VL, Leonart LP, Tonin FS, Borba HHL, Pontarolo R. Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies. Clin Drug Investig. 2018;38:389\u2013400.","journal-title":"Clin Drug Investig"},{"key":"1301_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.36076\/ppj.2009\/12\/819","volume":"12","author":"L Manchikanti","year":"2009","unstructured":"Manchikanti L, Datta S, Smith HS, Hirsch JA. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies. Pain Phys. 2009;12:819\u201350.","journal-title":"Pain Phys"},{"key":"1301_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jrsm.1078","volume":"4","author":"HJ Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann HJ, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Res Synth Methods. 2013;4:49\u201362.","journal-title":"Res Synth Methods."},{"key":"1301_CR21","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"1301_CR22","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane. 2022."},{"key":"1301_CR23","doi-asserted-by":"publisher","first-page":"e59202","DOI":"10.1371\/journal.pone.0059202","volume":"8","author":"RM Turner","year":"2013","unstructured":"Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS ONE. 2013;8:e59202.","journal-title":"PLoS ONE"},{"key":"1301_CR24","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2023. www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 8 Aug 2023."},{"key":"1301_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12883-022-02710-5","volume":"22","author":"T Alsaadi","year":"2022","unstructured":"Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. BMC Neurol. 2022;22:221.","journal-title":"BMC Neurol"},{"key":"1301_CR26","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020;60:2454\u201362.","journal-title":"Headache"},{"key":"1301_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. 2021;22:151.","journal-title":"J Headache Pain"},{"issue":"23","key":"1301_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","volume":"2022","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R, et al. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain. 2022;2022(23):139.","journal-title":"J Headache Pain"},{"key":"1301_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav. 2021;11: e2260.","journal-title":"Brain Behav"},{"key":"1301_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C. Long-term (48\u00a0weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache. 2021;61:1351\u201363.","journal-title":"Headache"},{"key":"1301_CR31","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/head.14291","volume":"62","author":"WJ Becker","year":"2022","unstructured":"Becker WJ, Spacey S, Leroux E, Giammarco R, Gladstone J, Christie S, et al. A real-world, observational study of erenumab for migraine prevention in Canadian patients. Headache. 2022;62:522\u20139.","journal-title":"Headache"},{"key":"1301_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","volume":"22","author":"R Belv\u00eds","year":"2021","unstructured":"Belv\u00eds R, Irimia P, Pozo-Rosich P, Gonz\u00e1lez-Oria C, Cano A, Viguera J, et al. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain. 2021;22:74.","journal-title":"J Headache Pain"},{"key":"1301_CR33","first-page":"8","volume":"74","author":"A Caso-Gonz\u00e1lez","year":"2022","unstructured":"Caso-Gonz\u00e1lez A, Leralta-Gonz\u00e1lez C, Sanz-Alonso V, Iturbe-Heras M, Hernando-de la B\u00e1rcena I, Obaldia-Ala\u00f1a C. Clinical experience with erenumab during the first year of treatment. JAMA Neurol. 2022;74:8\u201314.","journal-title":"JAMA Neurol"},{"key":"1301_CR34","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","volume":"42","author":"MM Cainazzo","year":"2021","unstructured":"Cainazzo MM, Baraldi C. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci. 2021;42:4193\u2013202.","journal-title":"Neurol Sci"},{"key":"1301_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-022-01456-2","volume":"23","author":"M Lowe","year":"2022","unstructured":"Lowe M, Murray L, Tyagi A, Gorrie G, Miller S, Dani K. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain. 2022;23:86.","journal-title":"J Headache Pain"},{"key":"1301_CR36","first-page":"2555","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E. Erenumab in chronic migraine: an Australian experience. Expert Rev Neurother. 2020;60:2555\u201362.","journal-title":"Expert Rev Neurother"},{"key":"1301_CR37","first-page":"61","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. Eur J Med Res. 2022;23:61.","journal-title":"Eur J Med Res"},{"key":"1301_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10194-022-01480-2","volume":"23","author":"R De Icco","year":"2022","unstructured":"De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, et al. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial. J Headache Pain. 2022;23:123.","journal-title":"J Headache Pain"},{"key":"1301_CR39","first-page":"3297","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Expert Opin Drug Saf. 2021;42:3297\u2013303.","journal-title":"Expert Opin Drug Saf"},{"key":"1301_CR40","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1111\/ene.15075","volume":"28","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. Eur J Neurol. 2021;28:4194\u2013203.","journal-title":"Eur J Neurol"},{"key":"1301_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12883-021-02507-y","volume":"21","author":"BBK Dinh","year":"2021","unstructured":"Dinh BBK, Aziz WH, Terruzzi A, Krieger DW. Initial experience with novel CGRP-receptor inhibitor therapy in migraine in the United Arab Emirates: a retrospective observational study. BMC Neurol. 2021;21:486.","journal-title":"BMC Neurol"},{"key":"1301_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23:47.","journal-title":"J Headache Pain"},{"key":"1301_CR43","first-page":"12","volume":"2021","author":"A Tziakouri","year":"2021","unstructured":"Tziakouri A, Tsangari H, Michaelides C. Assessment of the effect of erenumab on efficacy and quality-of-life parameters in a cohort of migraine patients with treatment failure in Cyprus. Front Neurol. 2021;2021:12.","journal-title":"Front Neurol"},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/ene.15364","volume":"29","author":"M Khalil","year":"2022","unstructured":"Khalil M, Moreno-Ajona D. Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022;29:2473\u201380.","journal-title":"Eur J Neurol"},{"key":"1301_CR45","first-page":"705","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Neurol Sci. 2022;42:705\u201314.","journal-title":"Neurol Sci"},{"key":"1301_CR46","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:61.","journal-title":"J Headache Pain"},{"key":"1301_CR47","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1007\/s00415-022-11226-4","volume":"269","author":"C Altamura","year":"2022","unstructured":"Altamura C, Brunelli N. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022;269:5848\u201357.","journal-title":"J Neurol"},{"key":"1301_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107169","volume":"214","author":"D Mahovi\u0107","year":"2022","unstructured":"Mahovi\u0107 D, Bra\u010di\u0107 M, Jaku\u0161 L, Vukovic Cvetkovic V, Krpan M. Effectiveness and safety of erenumab in chronic migraine: a Croatian real-world experience. Clin Neurol Neurosurg. 2022;214: 107169.","journal-title":"Clin Neurol Neurosurg"},{"key":"1301_CR49","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ene.15236","volume":"29","author":"C Zecca","year":"2022","unstructured":"Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, et al. Clinic and genetic predictors in response to erenumab. Eur J Neurol. 2022;29:1209\u201317.","journal-title":"Eur J Neurol"},{"key":"1301_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, Lamerato L, Krasenbaum LJ, Cohen JM, Tangirala K, Thompson S, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22:156.","journal-title":"J Headache Pain"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neurop.2022.01.009","volume":"2","author":"E Morales Bacas","year":"2022","unstructured":"Morales Bacas E, Portilla Cuenca JC, Romero Cantero V, Garc\u00eda Gorostiaga I, Mart\u00ednez Acevedo M, Casado-Naranjo I. Experience with erenumab: data from real clinical practice. Neurol Perspect. 2022;2:111\u20136.","journal-title":"Neurol Perspect."},{"key":"1301_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21:32.","journal-title":"J Headache Pain"},{"key":"1301_CR53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G, et al. Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain. 2020;21:102.","journal-title":"J Headache Pain"},{"key":"1301_CR54","first-page":"12","volume":"2021","author":"R Ornello","year":"2021","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B, et al. Gender differences in 3-month outcomes of erenumab treatment\u2014study on efficacy and safety of treatment with erenumab in men. Front Neurol. 2021;2021:12.","journal-title":"Front Neurol"},{"key":"1301_CR55","first-page":"38","volume":"23","author":"R Ornello","year":"2022","unstructured":"Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B, et al. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. Pain Manag. 2022;23:38.","journal-title":"Pain Manag"},{"key":"1301_CR56","first-page":"1273","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Brain Sci. 2022;43:1273\u201380.","journal-title":"Brain Sci"},{"key":"1301_CR57","first-page":"11","volume":"2020","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. Erenumab in Chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: a dual-center retrospective observational study. Front Neurol. 2020;2020:11.","journal-title":"Front Neurol"},{"key":"1301_CR58","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","volume":"23","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli B, Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, et al. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain. 2022;23:40.","journal-title":"J Headache Pain"},{"key":"1301_CR59","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60:2014\u201325.","journal-title":"Headache"},{"key":"1301_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto-di-Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21:69.","journal-title":"J Headache Pain"},{"key":"1301_CR61","first-page":"4","volume":"2021","author":"H Salem-Abdou","year":"2021","unstructured":"Salem-Abdou H, Simonyan D, Puymirat J. Identification of predictors of response to erenumab in a cohort of patients with migraine. Cephalalgia Rep. 2021;2021:4.","journal-title":"Cephalalgia Rep."},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21:84.","journal-title":"J Headache Pain"},{"key":"1301_CR63","first-page":"834","volume":"11","author":"F Schiano-di-Cola","year":"2021","unstructured":"Schiano-di-Cola F, Caratozzolo S, Venturelli E, Balducci U, Sidoti V, Pari E, et al. Erenumab discontinuation after 12-month treatment: a multicentric, observational real-life study. Neurol Clin Pr. 2021;11:834\u20139.","journal-title":"Neurol Clin Pr."},{"key":"1301_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","volume":"41","author":"F Schiano-di-Cola","year":"2020","unstructured":"Schiano-di-Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, et al. Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci. 2020;41:489\u201390.","journal-title":"Neurol Sci"},{"key":"1301_CR65","first-page":"12","volume":"2021","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P. Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol. 2021;2021:12.","journal-title":"Front Neurol"},{"key":"1301_CR66","first-page":"69","volume":"23","author":"M Silvestro","year":"2022","unstructured":"Silvestro M, Tessitore A, Orologio I, De Micco R, Tartaglione L, Trojsi F, et al. Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. Headache. 2022;23:69.","journal-title":"Headache"},{"key":"1301_CR67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","volume":"22","author":"A Straube","year":"2021","unstructured":"Straube A, Stude P, Gaul C, Schuh K, Koch M. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain. 2021;22:133.","journal-title":"J Headache Pain"},{"key":"1301_CR68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s10194-022-01515-8","volume":"23","author":"AR Gantenbein","year":"2022","unstructured":"Gantenbein AR, Agosti R, Kamm CP, Landmann G, Meier N, Merki-Feld GS, et al. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. J Headache Pain. 2022;23:142.","journal-title":"J Headache Pain"},{"key":"1301_CR69","first-page":"814","volume":"47","author":"A Viudez-Mart\u00ednez","year":"2022","unstructured":"Viudez-Mart\u00ednez A, Pascual-Carrasco A, Beltr\u00e1n-Blasco I, Hernandez-Lorido R. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study. Cephalalgia. 2022;47:814\u201323.","journal-title":"Cephalalgia"},{"key":"1301_CR70","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13760-021-01770-7","volume":"122","author":"P Storch","year":"2022","unstructured":"Storch P, Burow P, M\u00f6ller B, Kraya T, Heintz S, Politz N, et al. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice. Acta Neurol Belg. 2022;122:931\u20137.","journal-title":"Acta Neurol Belg"},{"key":"1301_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-0038-1646946","volume":"38","author":"D Saylor","year":"2018","unstructured":"Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38:182\u201390.","journal-title":"Semin Neurol"},{"key":"1301_CR72","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631\u201349.","journal-title":"Neurol Clin"},{"issue":"Suppl 1","key":"1301_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332.","journal-title":"Headache"},{"key":"1301_CR74","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s10194-022-01471-3","volume":"23","author":"C Rosignoli","year":"2022","unstructured":"Rosignoli C, Ornello R, Onofri A, Caponnetto V, Grazzi L, Raggi A, et al. Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain. 2022;23:100.","journal-title":"J Headache Pain"},{"key":"1301_CR75","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Society the B of D of the AH. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache J Head Face Pain. 2021;61:1021\u201339.","journal-title":"Headache J Head Face Pain."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01301-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T04:19:01Z","timestamp":1695356341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01301-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01301-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"13 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vinicius L. Ferreira: designed the study, collected and analysed the data, undertook the statistical analysis, wrote the first draft of the manuscript and approved the final version of the manuscript. Felipe F. Mainka: analysed the data, undertook the statistical analysis, wrote the first draft of the manuscript\u00a0and approved the final version of the manuscript. Astrid Wiens: edited and reviewed the\u00a0manuscript and approved the final version of the manuscript. Roberto Pontarolo: conceptualized and designed the study, supervised the project and approved the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data are included in the manuscript and the supplementary material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}